Central Miami Medical Institute | Miami, FL

Research site

(Unclaimed)

Location

719 NW 13th Ave, Miami, Florida, United States of America

Site insights

Top conditions

Top treatments

Troriluzole

Simufilam

KarXT

Semaglutide

SEP-4199

Psilocybin

SEP-363856

Masupirdine

ACP-204

AVP-786

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 13 total trials

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER)

Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in ba...

Enrolling

Treatment Resistant Depression

Device: Vagus Nerve Stimulation (VNS)

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.Participants will either get sem...

Active, not recruiting

Early Alzheimer´s Disease

Drug: Placebo (semaglutide)

Drug: Semaglutide

A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder

Demonstrate ability of SEP-363856 to be superior to placebo as an adjunctive therapy to ADT in change from baseline in depressive symptoms (MADRS \&...

Active, not recruiting

Major Depressive Disorder

Other: Placebo

Drug: SEP-363856

ACP-204 in Adults With Alzheimer's Disease Psychosis

This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies...

Enrolling

Alzheimer's Disease Psychosis

Drug: Placebo

Drug: ACP-204

Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compul...

Enrolling

Obsessive-Compulsive Disorder

Drug: Placebo

Drug: Troriluzole

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)

Enrolling

Treatment Resistant Depression

Drug: Psilocybin

Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only

Obsessive Compulsive Disorder

Drug: Troriluzole (BHV-4157)

Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatmen...

Enrolling

Agitation

Alzheimer's Type Dementia

Drug: Masupirdine 100 mg

Drug: Placebo